For 2025, this approach positions MEDVi as a trusted, cost-effective telehealth provider advancing ethical, affordable medical weight management
Understanding this distinction helps patients and providers navigate treatment options, insurance coverage, and medication costs while avoiding counterfeit or inappropriate alternatives
Semaglutide: Targets the GLP-1 pathway only Focuses on appetite regulation and fullness Tirzepatide: Targets both GLP-1 and GIP pathways May create a broader metabolic response Although this difference sounds technical, it can influence how patients respond to treatment
Patients considering these treatments should discuss their individual risk profile with their prescribing clinician, particularly if they have a history of pancreatic disease
Before considering outdated semaglutide, always consult your healthcare provider